On this page
Since LAM occurs almost exclusively in women of reproductive age, researchers believe the hormone estrogen might be involved in the abnormal muscle cell growth that characterizes the disease. Although there is no direct evidence that there is a relationship between estrogen and LAM, the treatment of LAM has focused on reducing the production or effects of estrogen. This could include estrogen or other hormone suppressing drugs. Additionally, doctors believe pregnancy may accelerate the progression of LAM. Women with LAM are urged to speak with a health care professional before getting pregnant.
- How Is LAM Treated?. National Heart Lung and Blood Institute (NHLBI). December 26, 2013; http://www.nhlbi.nih.gov/health/health-topics/topics/lam/treatment.html. Accessed 7/21/2014.
- Treating LAM. The LAM Foundation. 2014; http://www.thelamfoundation.org/lam-treatment. Accessed 7/21/2014.
- ClinicalTrials.gov lists trials that are studying or have studied Lymphangioleiomyomatosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
The Rare Lung Diseases Consortium: Molecular Pathway-Driven Diagnostics and Therapeutics for Rare Lung Diseases is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research involving pulmonary alveolar proteinosis, Hermansky-Pudlak Syndrome, and Lymphangioleiomyomatosis. A pilot project program supports research into other rare lung diseases that complement the main research projects.
The FDA has approved this product to be used in this manner.
|Treatment of lymphangioleiomyomatosis|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information